SymBio PharmaceuticalsSymBio Pharmaceuticals Limited4582東証グロース医薬品FY ending Dec 2025, consolidated, J-GAAP

SymBio Pharmaceuticals FY ending Dec 2019 results

SymBio Pharmaceuticals brought in ¥2.84B in revenue.

It lost about ¥152 for every ¥100 of sales at the operating level.

Where the money goes

Where ¥100 of sales goes

For every ¥100 SymBio Pharmaceuticals sells, how much goes where, and how much is kept.

FY ending Dec 2019
Cost of sales
¥70
SG&A
¥182
Operating loss
¥152
Net loss
¥154

Margin funnel (derived from reported values)Gross margin 30.5% → Operating margin -151.6% → Net margin -154.2%

Sources

Show source documents (2)
  • EDINET (FSA Japan)

    有価証券報告書-第17期(令和3年1月1日-令和3年12月31日)

    ID S100NPZC2022-03-29Open
  • EDINET (FSA Japan)

    有価証券報告書-第16期(令和2年1月1日-令和2年12月31日)

    ID S100L0KX2021-03-24Open

Extracted from XBRL: 34 / Derived from other figures: 2

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.